Continuous glucose monitoring (CGM) is not simply a sensor that produces a glucose number. A reliable system combines sensing chemistry, electronics, software, adhesives, data transmission, alarms, labeling, and clinical evidence. For anyone evaluating iCan CGM, suppliers, or technology partners, the key question is whether the complete development and manufacturing process is controlled against relevant quality and safety requirements.
Start With a Medical-Device Quality System
At the organizational level, ISO 13485:2016 is a central reference. ISO describes it as the international standard for quality management systems used in medical-device design and manufacture. It was reviewed and confirmed in 2025, so ISO 13485:2016 remains current.
For CGM, this matters because quality cannot be created by final inspection alone. A mature quality system should connect design controls, supplier management, production processes, complaint handling, traceability, and post-market activities. These processes help manufacturers maintain consistency as products move from development into routine production.
Accuracy Needs More Than a Low MARD
CGM accuracy deserves special attention because users and clinicians depend on both readings and glucose trends. CLSI POCT05, Performance Metrics for Continuous Interstitial Glucose Monitoring, provides guidance on point and trend accuracy, threshold alerts, system stability and reliability, clinical studies, calibration, measurement traceability, cybersecurity, and labeling.
This helps explain why a single MARD figure should not be treated as the whole quality story. Test conditions, reference methods, sensor location, user population, and study design can affect reported performance. A technical review should examine the protocol behind an accuracy claim rather than compare headline numbers alone.
This is illustrated by the published performance specifications of the iCan CGM.Its official FAQ reports an adult MARD of 8.71% when the sensor is worn on the abdomen over 15 days, while also providing separate values for children, adolescents, and upper-arm placement.This makes performance evaluation part of a broader device ecosystem rather than an isolated measurement.
Manage Risk from the Sensor to the App
ISO 14971:2019 provides the core framework for medical-device risk management. It covers identifying hazards, evaluating and controlling risks, and monitoring controls throughout the device life cycle.
In a CGM system, risk analysis can extend beyond sensor accuracy. Potential issues may involve insertion, skin contact, signal interruption, Bluetooth communication, alarm logic, or data processing. A strong quality program links important hazards to defined controls and verification.
Biocompatibility is another checkpoint because the sensor and adhesive interact with the body. ISO 10993-1 provides principles for evaluating the biological safety of medical devices within a risk-management process, including consideration of materials and tissue contact.
Software, Usability, and Connected Data Are Part of Quality
Modern CGM devices depend heavily on apps and connected software. IEC 62304 remains an important reference for medical-device software life-cycle processes, while IEC 62366-1 establishes a usability-engineering process for identifying and reducing use-related risks.
These standards matter because a technically accurate sensor can still present system-level or use-related risks if an app displays information unclearly, handles errors poorly, or presents alarms in ways users may misunderstand. Software verification therefore needs to be considered alongside sensor performance.
Cybersecurity is another part of the quality discussion. Secure pairing, access control, software updates, and resilient communication are increasingly relevant to connected medical devices, particularly when glucose information is transmitted between a sensor, mobile application, and cloud-based services.
Clinical Evidence and Clear Information Complete the Picture
Clinical evidence should be assessed alongside laboratory and engineering tests. Clinical investigation frameworks help establish whether a device performs as intended in the population and conditions for which it is designed.
At the user-facing level, information quality also matters. Identification, labeling, symbols, instructions, contraindications, warnings, and operating information all influence whether users can safely understand and operate a CGM system.
For companies such as Sinocare, the digital experience is also part of how users interact with a CGM platform. The associated mobile application provides readings every three minutes, glucose graphs, customizable alerts, event recording, and professional reports including AGP and time-in-range data. These functions show why connected data management should be considered when evaluating the overall quality of a CGM platform.
What Should Buyers Look for in a CGM Partner?
When comparing CGM manufacturers, it is useful to request evidence across the entire product life cycle. Ask how accuracy studies were designed, which reference methods were used, how manufacturing changes are controlled, how software is verified, how biocompatibility is assessed, and how complaints or field signals feed back into corrective action.
A useful review can also examine how a supplier handles product iteration, technical documentation, quality traceability, and user support. These details often reveal whether quality requirements are embedded into the manufacturing process or treated mainly as a certification exercise.
The iCan portfolio illustrates why CGM evaluation should consider the complete system rather than one specification. It combines continuous reading, app-based visualization, alerts, and published performance data, while its wider development approach integrates biosensing with digital health management.This broader integration reinforces why sensing technology, software, and data management should be evaluated as parts of the same system.
Conclusion
For CGM, meaningful quality is multi-layered. Quality-management and risk-management systems provide the foundation, while accuracy evaluation, biocompatibility, software, usability, cybersecurity, clinical evidence, and labeling address different parts of the overall system.
The practical lesson is to evaluate the evidence behind accuracy claims, the controls behind manufacturing, and the reliability of the sensor-to-app experience. Looking at these elements together gives healthcare organizations, distributors, and technology partners a more complete basis for assessing CGM quality.
